



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,025	08/16/2006	Yixin Wang	VDX5006USPCT	5348
27777	7590	04/23/2008	EXAMINER	
PHILIP S. JOHNSON JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			BAUSCH, SARAE L	
ART UNIT	PAPER NUMBER			
1634			MAIL DATE	DELIVERY MODE
			04/23/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/567,025	Applicant(s) WANG ET AL.
	Examiner SARAE BAUSCH	Art Unit 1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 02 February 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-221 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-221 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/DS/02) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 21-28, 33-34, 57-64, 93-100, 130-136, drawn to method of identifying melanoma by nucleic acid detection.

Group II, claim(s) 35-36, 71-72, 107-108, 143-144, drawn to method of identifying melanoma by protein detection.

Group III, claim(s) 165-173, 201-208, drawn to method of treating melanoma using nucleic acids detection methods.

Group IV, claim(s) 179-180, 215-216, drawn to method of treating melanoma using protein detection methods.

Group V, claim(s) 217-221, drawn to nucleic acids.

2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is identifying melanoma by expression of L1CAM or PLAB. Fogel et al. (Cancer Letters, 2003, cited on IDS) teaches expression of L1 adhesion molecule (L1CAM) in human malignant melanoma (see abstract, materials and methods pg. 238-239) Thus, the technical feature linking the recited groups I-V does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a

contribution over the prior art.

3. Claims 1-20, 29-32, 37-56, 65-70, 73-92, 101-106, 109-129, 137-142 link(s) inventions group I and group II. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claim 1-20, 29-32, 37-56, 65-70, 73-92, 101-106, 109-129, 137-142.

4. Claims 145-164, 173-178, 181-200, 209-214 link(s) inventions group III and group IV. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claim 145-164, 173-178, 181-200, 209-214.

Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 **Claims that require all the limitations of an allowable linking claim** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Further Restriction Requirement

5. The claims are drawn to methods which require identifying expression levels of SEQ ID No. 1 and SEQ ID No. 2, or SEQ ID No.1, 2, and 3, or the combination of primer/probe sets. Additional claims require further comprising determining expression of additional genes in a tissue sample to identifying melanoma. The claims are directed to numerous distinct methods recited in the alternative. For example, claim 5, the language “at least one gene” requires that one, two, three or any number more up to the 949 recited SEQ ID No. are detected within a target tissue sample. For example, a method requiring SEQ ID No. 1 and SEQ ID No. 2 is distinct from a method requiring SEQ ID No. 1-3 because the methods have a different mode of operation, do not overlap in scope, and they are not obvious variants of one another (see MPEP 806.05(j)). Each of the genes are structurally distinct compounds and encode distinct proteins. Applicant is required to elect a specific combination of genes and specific primer/probe pair that corresponds to the elected genes.

The claims further encompass many subcombinations which are disclosed as usable together in a single combination and which are also separately usable. For example, consider the following combinations:

Subcombination (A): SEQ ID No. 1, SEQ ID no. 2, SEQ ID no. 29

Subcombination (B): SEQ ID No. 1-3, SEQ ID no. 30.

Combination (A+B): SEQ ID No. 1, 2, 3, and, SEQ ID No. 29-30.

Each of the combinations of SEQ ID Nos are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In this case subcombinations (A) and (B) do not overlap in scope and there is no evidence on the record to suggest that they are obvious variants of one another. The subcombinations are separately usable as evidenced by their presentation in the alternative within the claims. Further, subcombination "A" has separate utility such as detecting the genes, as a marker. So, subcombinations (A) and (B) are distinct. See MPEP § 806.05(d).

These subcombinations are also distinct from the combination which comprises them because the combination does not require the particulars of the subcombination as claimed to show novelty or unobviousness and the subcombinations have utility by themselves or in another combination. The fact that the claim encompasses an embodiment which relies on only subcombination (B) is evidence that the details of subcombination (A) are not required for patentability of the combination (A+B), and likewise, the fact that the claim encompasses an embodiment which relies on only subcombination (A) is evidence that the details of subcombination (B) are not required for patentability of subcombination (A+B). The fact that the claim encompasses embodiments which use only subcombination (A) or subcombination (B) is evidence that the subcombinations have utility by themselves.

This example particularly discusses only the combinations (A), (B) and (A+B), but the same analysis could be applied to each of the different subcombinations and combinations set forth in the instant claims.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Each SEQ ID No., thus gene, must be searched by a separate query of the electronic databases. See MPEP 808.02(C). Therefore, a search for methods which use each SEQ ID no. or each combination of SEQ ID No. is not co-extensive with methods which use each other SEQ ID no or each other combination of SEQ ID No, and subsequently, the search and examination for every SEQ ID No. and every combination of SEQ ID No poses an enormous and serious burden on the examiner.

Applicant is required to select a single invention, ie, a single SEQ ID No. or a single combination of SEQ ID no. required for the claimed method. Applicant is further required to elect the primer/probe pair that corresponds to the elected SEQ ID no. (as recited in claim 37, 109, 181, 217). The invention may be a single SEQ ID No., a combination of more than one SEQ ID No. but less than all of the disclosed SEQ ID No or a combination of all possible claimed SEQ ID Nos. However, an election of a single invention, ie, a single SEQ ID No or a single combination of SEQ ID No is required. This restriction requirement is predicated on the fact that the methods which use different SEQ ID No or different combinations of SEQ ID No do not appear obvious over one another. Should applicant traverse on the ground that the different SEQ ID No or different combinations of SEQ ID No are not patentably distinct over each other , applicant should submit evident or identify such evidence now of record showing the inventions to be obvious variant over each other or clearly admit on the record that this is the

Art Unit: 1634

case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other inventions.

Applicant is also required to identify which claims read upon the elected invention.

The examiner has required restriction between subcombinations usable together. Where applicant elects a subcombination and claims thereto are subsequently found allowable, any claim(s) depending from or otherwise requiring all the limitations of the allowable subcombination will be examined for patentability in accordance with 37 CFR 1.104. See MPEP § 821.04(a). Applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined

claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarac Bausch whose telephone number is (571) 272-2912. The examiner can normally be reached on M-F 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Sarac Bausch/
Primary Examiner, Art Unit 1634